Brolucizumab for treating wet age-related macular degeneration [ID1254]
In development [GID-TA10455] Expected publication date: 03 February 2021
Search results
530 results
-
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]
In development [GID-TA10485] Expected publication date: 23 June 2021
-
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]
In development [GID-TA10670] Expected publication date: TBC
-
AR101 for treating peanut allergy [ID1282]
In development [GID-TA10713] Expected publication date: TBC
-
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID1680]
In development [GID-TA10551] Expected publication date: 10 February 2021
-
Pegcetacoplan for previously treated paroxysmal nocturnal haemoglobinuria [ID3746]
In development [GID-TA10651] Expected publication date: 02 February 2022
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]
In development [GID-TA10529] Expected publication date: 10 March 2021
-
Mepolizumab for treating severe eosinophilic asthma [ID3750]
In development [GID-TA10622] Expected publication date: 03 February 2021
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC
-
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
-
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis
In development [GID-DT9] Expected publication date: TBC
-
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
In development [GID-DT14] Expected publication date: TBC
-
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care
In development [GID-DT28] Expected publication date: TBC
-
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)
In development [GID-MT130] Expected publication date: TBC
-
Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)
In development [GID-MT163] Expected publication date: TBC
-
Microthane implants for breast reconstruction or breast augmentation (discontinued)
In development [GID-MT267] Expected publication date: TBC
-
SILK artery reconstruction device (discontinued)
In development [GID-MT81] Expected publication date: TBC
-
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)
In development [GID-MT516] Expected publication date: TBC
-
OraQuick® HCV Rapid Antibody Test (discontinued)
In development [GID-MT117] Expected publication date: TBC
-
The Assurance Nasal Alar SpO2 Sensor (discontinued)
In development [GID-MT510] Expected publication date: TBC
-
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
In development [GID-MT517] Expected publication date: TBC
-
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)
In development [GID-MT536] Expected publication date: TBC
-
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
In development [GID-TA10254] Expected publication date: TBC
-
Luspatercept for treating beta-thalassaemia ID1554
In development [GID-TA10506] Expected publication date: TBC
-
Kidney transplantation (rejection) - everolimus [ID117]
In development [GID-TAG241] Expected publication date: TBC
-
Eltrombopag for untreated severe aplastic anaemia ID1198
In development [GID-TA10284] Expected publication date: TBC
-
Pembrolizumab with epacadostat for untreated malignant melanoma ID1423
In development [GID-TA10330] Expected publication date: TBC
-
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228
In development [GID-TA10203] Expected publication date: TBC
-
Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]
In development [GID-TA10149] Expected publication date: TBC
-
Bevacizumab for untreated malignant pleural mesothelioma (ID1183)
In development [GID-TA10197] Expected publication date: TBC
-
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
In development [GID-TAG321] Expected publication date: TBC
-
Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]
In development [GID-TAG482] Expected publication date: TBC
-
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250
In development [GID-TA10213] Expected publication date: TBC
-
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
In development [GID-TAG507] Expected publication date: TBC
-
Pembrolizumab for previously treated multiple myeloma (ID1139)
In development [GID-TA10193] Expected publication date: TBC
-
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
In development [GID-TAG511] Expected publication date: TBC
-
Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]
In development [GID-TAG508] Expected publication date: TBC
-
Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]
In development [GID-TA10018] Expected publication date: TBC
-
Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]
In development [GID-TA10033] Expected publication date: TBC
-
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]
In development [GID-TA10099] Expected publication date: TBC
-
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186
In development [GID-TA10289] Expected publication date: TBC
-
Kidney transplantation (rejection) - belatacept [ID87]
In development [GID-TAG239] Expected publication date: TBC
-
DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]
In development [GID-TA10143] Expected publication date: TBC
-
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
In development [GID-TA10261] Expected publication date: TBC
-
Binimetinib for treating melanoma [ID833]
In development [GID-TA10074] Expected publication date: TBC
-
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
In development [GID-TA10081] Expected publication date: TBC
-
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
In development [GID-TA10088] Expected publication date: 27 December 2017
-
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]
In development [GID-TA10087] Expected publication date: 27 December 2017
-
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
In development [GID-TA10070] Expected publication date: TBC
-
Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]
In development [GID-TAG526] Expected publication date: TBC